Home·Explore by Therapy·RETEVMO

RETEVMO (selpercatinib)

TherapyEli Lilly

RETEVMO (selpercatinib) from Eli Lilly is a targeted inhibitor for tumors driven by RET alterations.

Approvals
5
Indications
4
Biomarkers
1
Mapped tests
3

Where this therapy is approved with a companion diagnostic

Each row represents a defined combination of indication, biomarker criteria, and RETEVMO. Select a testing pathway to see the eligible companion diagnostic tests.

Indication-specific approvals

Approvals where RETEVMO is tied to a specific indication and biomarker definition.

IndicationBiomarker criteriaNotes
Non-Small Cell Lung Cancer (NSCLC)
Solid Tumor · Lung
RET
  • fusions
View testing pathway →
Medullary Thyroid Cancer (MTC)
Solid Tumor · Thyroid
RET
  • RET mutations (SNVs, MNVs, and deletions)
View testing pathway →
Thyroid Cancer (TC)
Solid Tumor · Thyroid
RET
  • fusions
View testing pathway →
Tumor-agnostic approvals

Approvals defined at the solid tumor level where biomarker criteria determine eligibility for RETEVMO.

LevelBiomarker criteriaNotes
Solid Tumors
RET
  • fusions

Tests used in these approvals

These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering RETEVMO for eligible patients.

Test
FoundationOne CDx
Foundation Medicine, Inc.
Method
NGS
Specimen
Tissue (FFPE)
1 approvalView test profile →
Test
Oncomine Dx Target Test
Life Technologies Corporation (ThermoFisher Scientific)
Method
NGS
Specimen
Tissue (FFPE)
3 approvalsView test profile →
Test
TruSight Oncology Comprehensive
Illumina, Inc.
Method
NGS
Specimen
Tissue (FFPE)
1 approvalView test profile →
This view is scoped to RETEVMO (selpercatinib). You can also see how it compares with other therapies and indications on the main Know Your Companions™ map.